Myriad Genetics
MYGN
MYGN
260 hedge funds and large institutions have $2.22B invested in Myriad Genetics in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 93 increasing their positions, 82 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.08% less ownership
Funds ownership: 107.84% → 107.76% (-0.08%)
13% less capital invested
Capital invested by funds: $2.56B → $2.22B (-$341M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
260
Holding in Top 10
–
Calls
$11.2M
Puts
$7.24M
Top Buyers
| 1 | +$21.8M | |
| 2 | +$16.3M | |
| 3 | +$15.3M | |
| 4 |
BlackRock
New York
|
+$9.62M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$5.19M |
Top Sellers
| 1 | -$20.4M | |
| 2 | -$16.9M | |
| 3 | -$8.78M | |
| 4 |
Two Sigma Advisers
New York
|
-$8.01M |
| 5 |
Millennium Management
New York
|
-$5.81M |